This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Requip IR

GlaxoSmithKline plc

Drug Names(s): Requip immediate-release, Ropinirole HCl, Repreve, Adartrel (EU)

Description: Requip is an orally administered dopamine agonist with high affinity for the D2 and D3 receptors. It also has moderate affinity for opioid receptors in vitro. Requip extended release is an oral once-daily formulation of Requip.

Deal Structure: Until 2009, all historical revenue for Requip (including the extended release formulation) was recorded under Requip IR.


Requip IR News

Pink Sheet ASK Filing Timeline


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug